A new vasoactive intestinal peptide antagonist discriminates VIP receptors on guinea pig trachea and human neuroblastoma cells.

Leroux F, Goossens JF, Pommery N, Hénichart JP

Regulatory peptides1 Jul 1994Cited by 5 (Europe PMC)

PMID7972935DOI10.1016/0167-0115(94)90044-2PepBankPUB-07972935

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In LA-N-2 human neuroblastoma cells, VIP had an IC50 of 5.4 nM in the binding displacement assay, against 52.2 nM for a VIP analog.
In plain wordsIn human nerve-tumor cells, VIP bound its receptor sites at a lower concentration than a VIP analog did.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableDisplacement of VIP binding, IC50
Study
humann: not reported in source
LA-N-2 human neuroblastoma cells
Comparator
VIP analog
Outcome group
Receptor activity and mechanism · Pharmacology
Studied dose
Dose not stated
Measurements
IC50
5.4 nM
VIP, LA-N-2 cells
Source sentences
Summary
the VIP analog was found to displace VIP from its binding sites on LA-N-2 human neuroblastoma cells (VIP IC50: 5.4 nM; VIP analog IC50: 52.2 nM)
Report a problemFND-0797293501

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement
In guinea pig tracheal smooth muscle, a VIP analog altered neither basal tone nor the VIP-induced relaxation.
In plain wordsIn lab tests on guinea pig windpipe muscle, a VIP analog did not change muscle tone or block the relaxation caused by VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEffect of VIP analog on basal tracheal tone and VIP-induced relaxation
Study
guinea pign: not reported in source
guinea pig tracheal smooth muscle
Outcome group
Receptor activity and mechanism · Respiratory
Source sentences
Summary
This peptide altered neither the basal guinea pig tracheal smooth muscle tonus nor the VIP-induced relaxation.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0797293502
03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cells)Activity measurement
In LA-N-2 human neuroblastoma cells, a VIP analog inhibited VIP-induced cyclic AMP production by 58% at 1 microM and 95% at 10 microM.
In plain wordsIn human nerve-tumor cells, a VIP analog blocked most of the cyclic AMP production that VIP caused.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseInhibition of VIP-induced cAMP production by VIP analog
Study
humann: not reported in source
LA-N-2 human neuroblastoma cells
Outcome group
Receptor activity and mechanism · Pharmacology
Measurements
Inhibition of cAMP production
58%
1 microM analog
Inhibition of cAMP production
95%
10 microM analog
Source sentences
Summary
to inhibit the VIP-induced cyclic AMP production of 58 +/- 15% at 1 microM and 95 +/- 2% at 10 microM.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0797293503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.